ES2662022T3 - Vacunas atenuadas de la gripe porcina y procedimientos de fabricación y uso de las mismas - Google Patents
Vacunas atenuadas de la gripe porcina y procedimientos de fabricación y uso de las mismas Download PDFInfo
- Publication number
- ES2662022T3 ES2662022T3 ES13740452.1T ES13740452T ES2662022T3 ES 2662022 T3 ES2662022 T3 ES 2662022T3 ES 13740452 T ES13740452 T ES 13740452T ES 2662022 T3 ES2662022 T3 ES 2662022T3
- Authority
- ES
- Spain
- Prior art keywords
- swine flu
- manufacturing
- administration
- attenuated swine
- use procedures
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 201000010740 swine influenza Diseases 0.000 title abstract description 9
- 230000002238 attenuated effect Effects 0.000 title abstract description 5
- 238000000034 method Methods 0.000 title description 6
- 238000004519 manufacturing process Methods 0.000 title description 2
- 241000371980 Influenza B virus (B/Shanghai/361/2002) Species 0.000 title 1
- 241000282898 Sus scrofa Species 0.000 abstract description 4
- 230000028993 immune response Effects 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 101150039660 HA gene Proteins 0.000 abstract 2
- 230000013595 glycosylation Effects 0.000 abstract 2
- 238000006206 glycosylation reaction Methods 0.000 abstract 2
- 206010022000 influenza Diseases 0.000 abstract 2
- 102220466218 Iduronate 2-sulfatase_S71N_mutation Human genes 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 102200115309 rs267607160 Human genes 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 206010070834 Sensitisation Diseases 0.000 description 9
- 229960005486 vaccine Drugs 0.000 description 8
- 230000001900 immune effect Effects 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 241000282887 Suidae Species 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261672398P | 2012-07-17 | 2012-07-17 | |
| US201261672398P | 2012-07-17 | ||
| PCT/US2013/050000 WO2014014726A1 (en) | 2012-07-17 | 2013-07-11 | Attenuated swine influenza vaccines and methods of making and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2662022T3 true ES2662022T3 (es) | 2018-04-05 |
Family
ID=48874529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13740452.1T Active ES2662022T3 (es) | 2012-07-17 | 2013-07-11 | Vacunas atenuadas de la gripe porcina y procedimientos de fabricación y uso de las mismas |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US9216211B2 (https=) |
| EP (1) | EP2874656B1 (https=) |
| JP (1) | JP6467672B2 (https=) |
| KR (1) | KR102027758B1 (https=) |
| CN (1) | CN104582725B (https=) |
| AU (2) | AU2013290597B2 (https=) |
| BR (1) | BR112015001020B1 (https=) |
| CA (1) | CA2879228C (https=) |
| DK (1) | DK2874656T3 (https=) |
| EA (1) | EA033027B1 (https=) |
| ES (1) | ES2662022T3 (https=) |
| HU (1) | HUE036110T2 (https=) |
| MX (1) | MX365880B (https=) |
| MY (1) | MY166879A (https=) |
| NZ (2) | NZ712713A (https=) |
| PH (1) | PH12015500095A1 (https=) |
| PL (1) | PL2874656T3 (https=) |
| PT (1) | PT2874656T (https=) |
| WO (1) | WO2014014726A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2874656T3 (pl) * | 2012-07-17 | 2018-04-30 | Merial, Inc. | Atenuowane szczepionki przeciw grypie świń oraz ich sposoby wytwarzania i zastosowanie |
| JP6839714B2 (ja) * | 2015-12-28 | 2021-03-10 | ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド | Ｍ Ｈｙｏ多重ワクチン及びその使用 |
| EA201991319A1 (ru) * | 2016-11-30 | 2019-11-29 | Вакцины аттенуированного свиного гриппа и способы их изготовления и применения | |
| CN106939355A (zh) * | 2017-03-01 | 2017-07-11 | 苏州系统医学研究所 | 一种流感病毒弱毒活疫苗毒株的筛选和鉴定方法 |
| CN107064499B (zh) * | 2017-03-15 | 2019-06-18 | 青岛蔚蓝生物制品有限公司 | 禽流感病毒np蛋白抗原表位多肽及其胶体金试纸盒 |
| JP2021508696A (ja) | 2017-12-22 | 2021-03-11 | コーダ−ジェニックス・インコーポレイテッドＣｏｄａ−Ｇｅｎｉｘ， Ｉｎｃ． | がん処置のためのコドン対脱最適化領域を有する組換え型ウイルス及びその使用法 |
| CN112040977A (zh) | 2018-03-08 | 2020-12-04 | 科达金尼克斯有限公司 | 减毒黄病毒 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US5585250A (en) | 1993-08-20 | 1996-12-17 | The United States Of America As Represented By The Department Of Health & Human Services | Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies |
| ES2241042T3 (es) | 1996-10-11 | 2005-10-16 | The Regents Of The University Of California | Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora. |
| US5980912A (en) | 1997-03-25 | 1999-11-09 | Zonagen, Inc. | Chitosan induced immunopotentiation |
| KR20060026854A (ko) | 2003-05-28 | 2006-03-24 | 위스콘신 얼럼나이 리서어치 화운데이션 | ＰｏｌⅡ 프로모터 및 리보자임을 갖는 재조합 인플루엔자벡터 |
| US7871626B2 (en) * | 2005-08-04 | 2011-01-18 | St. Jude Children's Research Hospital | Modified influenza virus for monitoring and improving vaccine efficiency |
| CA2690196A1 (en) * | 2007-06-18 | 2008-12-24 | Medimmune, Llc | Influenza b viruses having alterations in the hemaglutinin polypeptide |
| CA2716340A1 (en) | 2008-02-21 | 2009-08-27 | Biological Mimetics, Inc. | Immunogenic influenza composition |
| CN102985107A (zh) | 2010-01-24 | 2013-03-20 | 生物模仿公司 | 免疫性流感成分 |
| PL2874656T3 (pl) * | 2012-07-17 | 2018-04-30 | Merial, Inc. | Atenuowane szczepionki przeciw grypie świń oraz ich sposoby wytwarzania i zastosowanie |
-
2013
- 2013-07-11 PL PL13740452T patent/PL2874656T3/pl unknown
- 2013-07-11 KR KR1020157004138A patent/KR102027758B1/ko active Active
- 2013-07-11 NZ NZ712713A patent/NZ712713A/en unknown
- 2013-07-11 EA EA201500140A patent/EA033027B1/ru not_active IP Right Cessation
- 2013-07-11 CA CA2879228A patent/CA2879228C/en active Active
- 2013-07-11 PT PT137404521T patent/PT2874656T/pt unknown
- 2013-07-11 ES ES13740452.1T patent/ES2662022T3/es active Active
- 2013-07-11 MX MX2015000713A patent/MX365880B/es active IP Right Grant
- 2013-07-11 AU AU2013290597A patent/AU2013290597B2/en active Active
- 2013-07-11 DK DK13740452.1T patent/DK2874656T3/en active
- 2013-07-11 MY MYPI2015000100A patent/MY166879A/en unknown
- 2013-07-11 WO PCT/US2013/050000 patent/WO2014014726A1/en not_active Ceased
- 2013-07-11 BR BR112015001020-2A patent/BR112015001020B1/pt active IP Right Grant
- 2013-07-11 US US13/939,321 patent/US9216211B2/en active Active
- 2013-07-11 EP EP13740452.1A patent/EP2874656B1/en active Active
- 2013-07-11 CN CN201380043383.4A patent/CN104582725B/zh active Active
- 2013-07-11 NZ NZ704188A patent/NZ704188A/en unknown
- 2013-07-11 HU HUE13740452A patent/HUE036110T2/hu unknown
- 2013-07-11 JP JP2015523130A patent/JP6467672B2/ja active Active
-
2015
- 2015-01-14 PH PH12015500095A patent/PH12015500095A1/en unknown
- 2015-12-21 US US14/977,485 patent/US9623105B2/en active Active
-
2016
- 2016-04-27 AU AU2016202693A patent/AU2016202693B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2662022T3 (es) | Vacunas atenuadas de la gripe porcina y procedimientos de fabricación y uso de las mismas | |
| TWI620574B (zh) | 口蹄疫合成胜肽緊急疫苗 | |
| UA117732C2 (uk) | Парентеральна норовірусна вакцина | |
| JP2022538673A (ja) | アフリカ豚熱ワクチン | |
| JP2017535602A (ja) | 手足口病ワクチン、ならびにその製造方法及び使用方法 | |
| BR112020010466A2 (pt) | composições imunogênicas e vacinas contra zika, métodos de uso das mesmas | |
| Guilfoyle et al. | Protective efficacy of a polyvalent influenza A DNA vaccine against both homologous (H1N1pdm09) and heterologous (H5N1) challenge in the ferret model | |
| US20170368164A1 (en) | Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza | |
| Xu et al. | Evaluation of a chimeric multi-epitope-based DNA vaccine against subgroup J avian leukosis virus in chickens | |
| JP2020502080A (ja) | 弱毒ブタインフルエンザワクチン並びにその作製および使用方法 | |
| Martin et al. | Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus | |
| CN104159608A (zh) | 针对流感的改善的疫苗接种 | |
| US7601500B2 (en) | Prime-boost vaccine for the protection of equines against viral infection | |
| US9913896B2 (en) | Attenuated parvovirus vaccine for muscovy duck parvovirus and goose parvovirus (derzsy's disease) | |
| Borhani et al. | A comparative approach between heterologous prime-boost vaccination strategy and DNA vaccinations for rabies | |
| Huijun et al. | Enhancing effects of the chemical adjuvant levamisole on the DNA vaccine pVIR‐P12A‐IL18‐3C | |
| EP1987840A1 (en) | Prime-boost vaccine for the protection of equines against viral infection | |
| Wang et al. | The nanoemulsion adjuvant provides antigen dose-sparing effects and enhances maternal passive immune protection for the cell-cultured quadrivalent influenza virus subunit vaccine | |
| Sanchez | Enhancing Protective Immune Responses Elicited by Computationally Optimized Broadly Reactive Antigen (COBRA) Influenza Hemagglutinin and Neuraminidase Vaccines Using Novel Adjuvants | |
| Rincón Tabares et al. | Evaluation of the Safety and Immunogenicity of a Multiple Epitope Polypeptide from Canine Distemper Virus (CDV) in Mice | |
| Sanchez Sanchez et al. | Protective Efficacy of a Mucosal Influenza Vaccine Formulation Based on the Recombinant Nucleoprotein Co-Administered with a TLR2/6 Agonist BPPcysMPEG | |
| Li et al. | Construction and Evaluation of Quadruple‐Gene‐Deleted Pseudorabies Virus Platforms for ASFV Antigen Delivery | |
| Cao et al. | Functional analysis and epitope recognition of African swine fever virus pA151R antigen-specific T cells | |
| EP1779866A1 (en) | Prime-boost vaccine for the protection of equines against viral infection | |
| EP2076280B1 (en) | Feline influenza vaccine and method of use |